RNA therapeutics offer great potential to transform the biomedical landscape, encompassing
the treatment of hereditary conditions and the development of better vaccines. However, the …

Three decades have passed from the initial discovery of a microRNA (miRNA) in
Caenorhabditis elegans to our current understanding that miRNAs play essential roles in …

Current delivery strategies for cancer therapeutics commonly cause significant systemic side
effects due to required high doses of therapeutic, inefficient cellular uptake of drug, and poor …

We report asialoglycoprotein receptor (ASGPR)-targeted doxorubicin hydrochloride (Dox)
nanoparticles (NPs) for hepatocellular carcinoma (HCC). Polyethylene sebacate (PES) …

In the past decades, the striking development of cationic polypeptides and cell-penetrating
peptides (CPPs) tailored for small interfering RNA (siRNA) delivery has been fuelled by the …

Over the last decade, the use of targeted therapies has immensely increased in the
treatment of cancer. However, treatment for endometrial carcinomas (ECs) has lagged …

Ovarian cancer has shown little improvement in survival among advanced-stage patients
over the past decade. Current treatment strategies have been largely unsuccessful in …

Self‐assembling peptides are a popular vector for therapeutic cargo delivery due to their
versatility, tunability, and biocompatibility. Accurately predicting secondary and …

The cytosolic delivery of therapeutic proteins (eg, antibodies or enzymes) by cell-penetrating
peptides (CPPs), such as a human immunodeficiency virus-derived TAT peptide, is …

Cancer is a significant health concern worldwide and its clinical treatment presents many
challenges. Consequently, much research effort has focused on the development of new …